 |
|
|
|
 |
|
|
 Contact |  Print version |  PDF version |  Recommend company
|
Brunner Strasse 59
1235 Wien
Austria
|
|
Portrait
Nabriva has a diversified drug portfolio of novel antibacterials, addressing unmet medical need in the hospital and community setting. The company’s portfolio comprises five programs, one thereof being a clinical phase I program and two being at late preclinical stage, expected to enter clinical trials within the next 6 months. All programs have been identified and developed internally, emphasizing Nabriva’s powerful development expertise and strong proprietary position.
Industrial Sectors
Additional information
Nabriva Therapeutics AG
Wien, Austria
News
|
|
|
|
|
|
Top
